Highlights

• DAYBUE delivered record quarterly net sales of US$125 million in Q2 2026.
• Neuren’s quarterly royalty income climbed 34% year over year to US$12.9 million.
• Higher 2026 guidance, European expansion and a pending Japan trial update strengthened investor confidence.

Record Sales Trigger a Sharp Market RallyNeuren Pharmaceuticals Limited (ASX: NEU) attracted significant buying interest after its commercial partner, Acadia Pharmaceuticals, reported record quarterly sales for DAYBUE. NEU surged 17.22% to a current market price of AU$21.815 following the announcement.DAYBUE, also known as trofinetide, generated Q2 2026 net sales of US$125 million, representing growth of 30% from Q2 2025 and 24% from Q1 2026. The result marked the treatment’s strongest quarterly sales performance since its commercial launch.From an equity research perspective, the share-price response appears to reflect accelerating product adoption, improved royalty visibility and meaningful progress toward broader international commercialisation.STIX Adoption Drives Volume-Led GrowthThe sales increase was almost entirely driven by higher volumes, supported by stronger-than-anticipated adoption of DAYBUE STIX, the powder formulation introduced broadly across the United States in early April 2026.

By the end of the quarter, approximately 40% of US DAYBUE patients were receiving STIX. Around 45% of STIX demand came from new patients or individuals returning to treatment, indicating that the alternative formulation may be improving market reach and treatment accessibility.This adoption trend is strategically important because sustained prescription growth could strengthen DAYBUE’s commercial base beyond the initial launch population.Royalty Income Reaches a New HighNeuren earned US$12.9 million in royalty income during Q2 2026, increasing 34% from the prior corresponding period and 24% from Q1 2026.Acadia also raised its full-year 2026 DAYBUE sales guidance to US$480 million–US$510 million from the previous range of US$460 million–US$490 million. Consequently, Neuren’s expected CY2026 royalty income increased to US$53 million–US$56 million, compared with the earlier forecast of US$50 million–US$54 million.The upgraded outlook enhances near-term earnings visibility while Acadia’s reaffirmed US$700 million DAYBUE sales target for 2028 supports the longer-term revenue opportunity.European Launch Could Unlock Additional ValueDAYBUE’s international expansion remains another potential catalyst. The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorisation for patients aged five years and older with Rett syndrome.

Upon securing European Commission approval, the product would gain marketing access throughout the European Union's 27 member countries, alongside Iceland, Liechtenstein and Norway. A commercial launch in Germany is anticipated in early Q4 2026.

Following the first European commercial sale, Neuren would be entitled to receive US$35 million. The commercial agreement also provides for potential milestone payments of up to US$170 million linked to sales performance, while royalty rates are structured on a tiered basis from the mid-teen percentages to the low-20% range.Japan Readout Adds Another Upcoming CatalystIn Japan, topline results from the ongoing trofinetide clinical trial remain scheduled for release between September and November 2026. A regulatory submission is anticipated in 2027.A favourable trial outcome could support entry into another major pharmaceutical market and further diversify the geographical contribution from trofinetide.Broader Clinical Pipeline Supports Long-Term PotentialBeyond DAYBUE, Neuren is developing NNZ-2591, or ercanetide, across several serious neurodevelopmental conditions. The company is currently conducting a Phase 3 trial in children with Phelan-McDermid syndrome, alongside a 52-week open-label extension study.Although DAYBUE remains the principal commercial value driver, progress across the clinical pipeline could provide additional long-term optionality.OutlookNeuren’s sharp share-price increase reflects a combination of record DAYBUE sales, accelerating STIX adoption, upgraded royalty expectations and expanding international opportunities. The European launch, Japan trial readout and continued US prescription growth may remain key catalysts over the coming quarters.However, investors should continue monitoring regulatory timelines, product concentration, clinical execution and dependence on Acadia’s commercial performance. Overall, the latest update materially strengthens Neuren’s revenue outlook, although the substantial one-day rally may also increase near-term valuation sensitivity.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au